York-based Cizzle Biotechnology receives US clinical accreditation for lung cancer blood test

1 hour ago · Originally published 30 Sep 2026 9/10 Original headline: 'A breakthrough in saving lives': Cizzle's blood test for lung cancer accredited for clinical use i…

A blood test developed by York-based Cizzle Biotechnology to detect early-stage lung cancer has been accredited for clinical use in the US. The test identifies the CIZ1B biomarker and is now moving from development to commercialisation, with plans to validate the method for use within the NHS.

Source: Yorkshire Post North Yorkshire

Read the full story

About the AI positivity score

Report this article

Get your regular dose of good news

Follow the best stories on Bluesky or subscribe with your favourite feed reader.

Follow on Bluesky Subscribe via RSS

How AI positivity scores work

Scores out of ten are AI estimates of how uplifting a story is, not a measure of accuracy or importance. Different readers may feel differently. Headlines and summaries are AI-written; follow the source link for the original reporting.

How stories are selected